Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827968 | 0.90 | HTR2A (0.80) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| SCHEMBL20467771 | 0.87 | HTR2A (0.71) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| SCHEMBL6594172 | 0.86 | HTR2A (0.74) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| SCHEMBL12524469 | 0.86 | HTR2A (0.74) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| SCHEMBL4112112 | 0.86 | HTR2A (0.74) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| SCHEMBL14621621 | 0.86 | HTR2A (0.74) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| SCHEMBL4372706 | 0.86 | HTR2A (0.74) | HTR2AMAOBBCL9CTNNB1MAPT | |
| SCHEMBL14437515 | 0.86 | HTR2A (0.66) | HTR2AMAOBMAPTPLA2G4BCA12 | |
| Water SCHEMBL10938430 | 0.85 | HTR2A (0.73) | HTR2AMAOBL3MBTL1BCL9CTNNB1 | |
| Water SCHEMBL10938437 | 0.85 | HTR2A (0.73) | HTR2AMAOBL3MBTL1BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257712-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2016-09-08 | — | — | US | disclosed |
| US-9206222-B2 | Solid phase peptide synthesis of peptide alcohols | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-12-08 | — | — | US | disclosed |
| US-20150071918-A1 | PEPTIDES FOR THE TREATMENT OF CANCER | UNIVERSITY OF SOUTH FLORIDA | 2015-03-12 | — | — | US | disclosed |
| EP-2547693-B1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8853149-B2 | Integrin interaction inhibitors for the treatment of cancer | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130065837-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-03 | — | — | US | disclosed |
| US-7612069-B2 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| US-7601751-B2 | Indole acetic acid acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7368575-B2 | 6-alkylamino-2,2′-disubstituted-7,8-disubstituted-2H-1-benzopyran derivatives as 5-lipoxygenase inhibitor | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-05-06 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | HTR2A 430/4885MAOB 182/4885PTGS2 1649/4885 |
| US-20130065837-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | ITGB1, ITGB7, ITGA2B | HTR2A 4607/4885MAOB 4816/4885PTGS2 4574/4885 |
| US-20120108748-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF PEPTIDE ALCOHOLS | VIP, ERG28, PSAP | HTR2A 4587/4885MAOB 4270/4885PTGS2 4445/4885 |
| US-20160257712-A1 | INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER | ITGB1, ITGB7, ITGA2B | HTR2A 4607/4885MAOB 4816/4885PTGS2 4574/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | HTR2A 1646/4885MAOB 668/4885PTGS2 1447/4885 |
| US-20150071918-A1 | PEPTIDES FOR THE TREATMENT OF CANCER | CD44, PTK2, SDC1 | HTR2A 2961/4885MAOB 4683/4885PTGS2 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.